Savolitinib and osimertinib combination significantly improves PFS in EGFR-mutated NSCLC with MET amplification compared to ...

Findings from a literature review recently published in The American Journal of Public Health suggest that greater ...

During a live event, Omid Hamid, MD, discussed the logistics and multidisciplinary process of using tumor-infiltrating ...

Nivolumab plus AVD significantly improves PFS compared to brentuximab vedotin plus AVD in advanced-stage classic Hodgkin lymphoma, with a 91% vs 82% 3-year PFS rate. The PFS benefit of nivolumab plus ...

Segment 5 examines the patient’s response to first-line corticosteroids and uses it to discuss broader limitations of steroid ...

Dr Gordan defines financial toxicity as the multifaceted economic burden arising from the total cost of care. In oncology, ...

Segment 6 focuses on decision-making in second-line therapy for cGVHD, centering on the role of ruxolitinib. Dr. DeFilipp ...

Lung cancer incidence rates in the United States have undergone a significant transformation over the last several decades, ...

Results from the phase 3 ENDURE trial (NCT03117816), newly published in Leukemia, demonstrate that ropeginterferon alfa-2b ...

Findings from a phase I trial (NCT04183166) evaluating TG4050, a neoantigen therapeutic vaccine, in patients with operable, ...

Explore how community oncology reduces financial toxicity in cancer care, highlighting cost savings and quality benefits over ...

QUILT-3.055 is a basket trial evaluating nogapendekin alfa inbakicept across multiple solid tumor types. In the NSCLC cohort, ...